NDASUBCUTANEOUSSOLUTION
Approved
Feb 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
3/8 — Basic
ONAPGO (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d4 receptor, and moderate affinity for the dopamine d2, d3, and d5, and adrenergic α1d, α2b, α2c receptors. First approved in 2025.
Drug data last refreshed 5h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONAPGO is apomorphine hydrochloride, a non-ergoline dopamine agonist approved for Parkinson's disease in February 2025. It is administered subcutaneously as a solution and works by stimulating post-synaptic dopamine D2-type receptors in the brain, with high binding affinity for the D4 receptor and moderate affinity for D2, D3, D5, and adrenergic receptors. The precise mechanism in Parkinson's disease remains under investigation but is believed to involve dopaminergic pathway modulation.
LOE Approaching1.4 years to LOE
Recently approved with limited commercial data and challenging patent horizon (1.4 years remaining), suggesting a compressed growth window and lean team structure.
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of ONAPGO as a treatment for Parkinson's disease is unknown, although it is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Started Mar 2025
120 enrolled
Parkinson Disease
Why This Matters for Your Career
Worked on ONAPGO at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.